Nottingham University Hospitals NHS Trust investigated for potential corporate manslaughter offences
Nottinghamshire Police said its investigation follows deaths and serious injuries allegedly related to maternity care at the trust.
The force launched a criminal investigation in September 2023, after concerns were raised linked to maternity services at Nottingham University Hospitals (NUH) NHS Trust.
More than 2,000 experiences of maternity care at the trust are currently being looked at as part of the largest-ever NHS maternity review, led by former senior midwife Donna Ockenden.
The trust says it is "fully committed" to both the police investigation and the independent review.
The parents of a baby who was stillborn under the trust's care said the fresh investigation was "just one piece of the jigsaw towards accountability".
Dr Jack and Sarah Hawkins both worked for the trust, until the death of their daughter Harriet in 2016.
They said their lives were "completely destroyed by the unimaginable and repeated trauma".
"We will continue to fight for justice, not only for Harriet, but for all those whose lives have shattered," they added.
The Nottingham affected families group said in a statement that the investigation was "welcome" but that no probe would "ever reverse the harm and suffering".
Detective Superintendent Matthew Croome said the investigation into corporate manslaughter had now "formally commenced".
"The offences relates to circumstances where an organisation has been grossly negligent in the management of its activities, which has then led to a person's death," he added.
"In such an investigation, we are looking to see if the overall responsibility lies with the organisation rather than specific individuals, and my investigation will look to ascertain if there is evidence that the Nottingham University Hospitals NHS Trust has committed this offence."
Nick Carver, chair of the trust, and Anthony May, its chief executive, said they were "determined to improve our maternity services".
"We know how important the police investigation and independent review are for the affected families, the trust and our local communities," they added.
"We hope that affected families receive the answers that they deserve."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
27 minutes ago
- Daily Mail
Moment teen yobs are confronted in police 'catapult crackdown' after surge in wildlife attacks
Kent Police have released footage of officers stopping and searching teenagers for catapults following a wave of antisocial behaviour reports. The force says it's receiving up to 14 reports a day, including claims that the weapons are being used to harm pigeons and seagulls and cause criminal damage. Click the video above to watch.
South Wales Guardian
28 minutes ago
- South Wales Guardian
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
North Wales Chronicle
28 minutes ago
- North Wales Chronicle
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
